Form 4: Jazz Pharma Director Sells Shares, Gains RSUs

Jazz Pharmaceuticals plc Director Bruce C. Cozadd reported the sale of 18,000 ordinary shares and the acquisition of 2,506 restricted stock units.

Summary

• Director Bruce C. Cozadd reported transactions involving Jazz Pharmaceuticals plc (JAZZ) ordinary shares.
• On November 18, 2025, Cozadd sold a total of 18,000 ordinary shares across four separate transactions.
• The sales occurred at weighted average prices ranging from $180.0859 to $182.6009 per share.
• On November 20, 2025, Cozadd acquired 2,506 restricted stock units (RSUs) at a price of $0.0.
• These RSUs were granted under the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan and are expected to vest in full on July 24, 2026.
• Following these transactions, Cozadd's direct beneficial ownership of ordinary shares is 393,332.

Sentiment

Score: 5

Explanation: Director Bruce C. Cozadd reported both sales of ordinary shares and the acquisition of restricted stock units. While sales can be perceived negatively, the acquisition of RSUs indicates continued alignment with the company's long-term performance, resulting in a neutral overall sentiment for this routine insider filing.

Positives

• Acquisition of 2,506 restricted stock units (RSUs) by Director Bruce C. Cozadd on November 20, 2025, aligns his interests with long-term shareholder value.
• The RSUs were granted under an existing stock award plan, indicating a routine compensation component for non-employee directors.

Negatives

• Director Bruce C. Cozadd sold a total of 18,000 ordinary shares on November 18, 2025, potentially signaling a reduction in his direct equity exposure.
• The sales occurred at prices ranging from $180.0859 to $182.6009 per share.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance, focusing solely on insider transactions.

Industry Context

This filing is a routine insider transaction report and does not provide broader industry context or competitive analysis. It reflects individual director equity management rather than company-wide strategic shifts.

Stakeholder Impact

• Shareholders may observe a slight negative sentiment due to director share sales, though this is partially offset by the acquisition of restricted stock units, which aligns management incentives with long-term company performance.

Next Steps

• Vesting of 2,506 restricted stock units on July 24, 2026, subject to continuous service and other conditions.

Key Dates

Recommendation

The filing details routine insider transactions by Director Bruce C. Cozadd, involving both sales of ordinary shares and the acquisition of restricted stock units. These transactions do not provide a strong directional signal for the stock, suggesting a 'hold' recommendation for investors awaiting more substantive company news or financial performance updates.

Keywords

Jazz Pharmaceuticals, JAZZ, Form 4, Insider Trading, Share Sale, Restricted Stock Units, Director Transaction, Bruce C. Cozadd, Equity Compensation